TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incremental GLP-1 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maternal health outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Child health outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Grades II-IV aGVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Saliva Fluoride Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants completing 70% of exercise sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent increase in fitness as measured by the 6 minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of MSD ETEC diarrhoea
Endpoint domain: Adverse events/effects
Primary endpoint: blood pressure value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUCτ,ss of candesartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax,ss of candesartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUCτ,ss of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax,ss of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tumour pathological complete response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Uncorrected Intermediate Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplitude Required to Elicit the MEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of daily night food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of Cortical Excitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neonatal Facial Coding System - total facial score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of ABBV-157
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough Concentration (Ctrough) of ABBV-157
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Psoriasis Area and Severity Index (PASI) score from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monofollicular Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Fasting Triglyceride Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Continuous Use of Highly Effective Contraceptives
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Positive STI Test After Baseline Negative Test
Endpoint domain: Adverse events/effects
Primary endpoint: Initiation of Highly Effective Contraceptive Post Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Performance of e- Ab sensor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reach sufficient vitamin D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decrease disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unexpected rehospitalization for cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Initiation of maintenance dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Kidney transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Initiation or broadening of antibiotic for treatment of infection
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of kidney stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean SVC Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in Specific Treg memory cells at week 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients presenting adverse events related to study treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Ventricle repolarization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Identification success of amylose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OSCE checklist total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SIRI-2 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OSCE global rating total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Fine Lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in Smoothness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in Brightness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety as Assessed by Systolic Blood Pressure [mmHg]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety as Assessed by Diastolic Blood Pressure [mmHg]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Single dose pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local solicited symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: general solicited symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Unsolicited AE´s
Endpoint domain: Adverse events/effects
Primary endpoint: SAEs and pregnancies
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical evaluation - part I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood product utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Post operative atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EEG power spectral density (PSD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG signal coherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG signal entropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total Number of Participants With Leptomeningeal Metastasis Detected (ER Status)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total Number of Participants With Leptomeningeal Metastasis Detected (HER2 Status)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes of Memory immediate recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes of Memory delayed recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes of general cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Endtidal oxygen fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Average Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: good neurological outcome after thrombolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: poor neurological outcome after thrombolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ictal/post-ictal hypoxemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician Administered PTSD Scale (CAPS-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in BMIPP summed scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Psychological Threat
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physics Motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Variation of serum progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cerebral blood flow regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sexual Health Inventory for Men (SHIM)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of subjects with at least one fall adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Stool Form
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Abdominal Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Stool Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Adverse Events of PD0332991
Endpoint domain: Adverse events/effects
Primary endpoint: Degree of pain relief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Degree of complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Scar Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinician Scar Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of Permanent stroke
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in cortical thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in DTI indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of subjects with >/= 50% reduction in total symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hormonal status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Functional Cerebral Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients developing superficial thrombophlebitis
Endpoint domain: Adverse events/effects
Primary endpoint: Nocturnal Transcutaneous PCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cortex activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Treatment-Emergent Serious Adverse Events (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Achieving SLE Responder Index ≥4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAS peptide quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal and sub maximal exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pumping pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in left ventricular ejection fraction (LVEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clearance (Cl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in adiposity as measured by change in BMI z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total and low-density lipoprotein (LDL) cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LDL:HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Device success of implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lung Volume Initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HDL function as measured by cholesterol efflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Walking distances obtained with the 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean 28-day monthly vertigo frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dizziness Handicap Inventory scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Efficacy of treatment in diabetic macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: ART Adherence Behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients receiving evidence based therapies to reduce cardiovascular risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hypoxemia event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Admission Due to Complications Related to Portal Hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of PD-1/PDL-1 histologic staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Moderate to severe bronchopulmonary dysplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in mean Muscle Sympathetic Nerve Activity (MSNA) burst frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in High-sensitivity C-reactive Protein (hsCRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Serum Amyloid A (SAA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Effectiveness of oral anticoagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in pharmacodynamic markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Degree of consensus on the level of appropriateness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Postoperative lymphoceles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Fold Increase (GMFI) in Antibody Titre After Vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Evaluable Participants Achieving a HI Titre ≥ 40 or Single Radial Haemolysis (SRH) Area ≥ 25 mm2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in fasciculation frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of patients who have well tolerated the colonoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean grade of patient anxiety before endoscopy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Coronary Artery Diameter Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Infant Food Reinforcing Proportion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endogenous Thrombin Potential (ETP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lag Time of the thrombin generation curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Peak value of the thrombin generation curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Donors Reaching Stem Cell Target Collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of target lesion late lumen loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Per Clinical Outcome at End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Per Clinical Outcome at Follow-up Visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Study Participants Who Tolerated three vaccinations
Endpoint domain: Adverse events/effects
Primary endpoint: Endogenous (Hepatic) Glucose Output During High-dose Insulin Infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endogenous (Hepatic) Glucose Output During Low-dose Insulin Infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oral Glucose Absorption After Colesevelam
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Energy expenditure [kilocalories per minute]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy expenditure [metabolic equivalents]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Step counts [total number of steps taken]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Predicted Forced Vital Capacity (FVC-%))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Amount of horizontal bone gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Depth of central corneal ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of patients with objective manifestations of Lyme borreliosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of patients with subjective Lyme borreliosis-associated/post-Lyme borreliosis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Spontaneous Bowel Movement (SBM) Responder Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: health outcomes in participants with sickle cell disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeated bacteriological swab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: 2-year survival of patients
Endpoint domain: Mortality/survival
Primary endpoint: Ratio of normalized fluorescence intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in fear during the treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in anxiety during the treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Who Maintained Average Hb
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total Number of Deregulated Genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended-for-phase II dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wart characterization change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient rating of sleep-specific services
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: VO2 Peak (Oxygen Consumption at Peak Exercise)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriate communication
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Problem behavior
Endpoint domain: Adverse events/effects
Primary endpoint: Time until conversion to sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SpondyloArthritis International Society 20 Response Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of subjects with serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Stent Thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Brief symptom rating scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to recover from Delayed Graft Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes